Lexaria Bioscience Corp. (NASDAQ: LEXX) Working to Address Declining Antihypertensive Intensification and High Prescription Abandonment Rates, with DehydraTECH-CBD
Lexaria is a global innovator in drug delivery platforms developing DehydraTECH-CBD as a potential treatment for hypertension A 2022 study documented a decline in the percentage of patients receiving appropriate treatment intensification over the last ten years This decline has been attributed to, among other possible reasons, the side effects of antihypertensive drugs At the same time, only 24% of adults with hypertension have the condition under control, a statistic attributable to the medications’ troublesome side effects Lexaria’s investigations of its DehydraTECH-CBD have so far presented favorable safety and tolerability data, meaning its drug candidate could offer reprieve to millions…